Questions discussed in this category
How would you counsel the patient given the drug interactions present?
Would you continue KEYNOTE-522 neoadjuvant therapy? The patient has a PMH of sarcoidosis with no stroke risk factors. No residual deficits.
Do you prophylactically start all patients on B12, B-complex, and/or omega-3? If so, what dose? What about ice mittens and booties?
Are there contraindications to drugs like oxaliplatin or abraxane?
Does chronicity or severity of the patient's underlying symptoms play a role in yo...
Presuming that work-up for cardioembolic sources is negative, how would you proceed?
20521179301093612137101449444
Papers discussed in this category
Circulation, 2020 Feb 17
N. Engl. J. Med.,
J Clin Oncol, 2020 Jul 14
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-06-20
J Clin Oncol, 2019 Dec 19
Ann Oncol,
PloS one, 2017
Circulation, 2016-03-29
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991 Feb
Journal of stroke, 2020 Jan 31